Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Stalman, Eileen W; Eftimov, Filip; Kummer, Laura; Steenhuis, Maurice; Kempen, Zoé L E van; Killestein, Joep; Volkers, Adriaan; Tas, Sander W.; Boekel, Laura; Wolbink, Gertjan; Kooi, A. van der; Raaphorst, Joost; Löwenberg, Mark; Takkenberg, B.; D’Haens, Geert R.; Spuls, Phyllis I.; Bekkenk, Marcel W.; Musters, Annelie H; Post, Nicoline F; Bosma, Angela L.; Hilhorst, Marc; Vegting, Yosta; Bemelman, Frederique J; Voskuyl, Alexandre E.; Broens, Bo; Sanchez, Agner Parra; van, Cécile A. C. M.; Wit, Jelle de; Rutgers, Abraham; Leeuw, Karina de; Hórvath, Barbara; Verschuuren, Jan; Ruiter, Annabel M.; Ouwerkerk, Lotte van; Woude, Diane van der; Allaart, Cornelia F; Teng, Y K Onno; Paassen, Pieter van; Busch, Matthias; Jallah, Papay B P; Brusse, Esther; Doorn, Pieter A. van; Baars, Adája E.; Hijnen, Dirk Jan; Schreurs, Corine R G; Pol, W. Ludo van der; Goedee, H. Stephan; Keijzer, Sofie; Keijser, Jim; Cristianawati, Olvi; Brinke, Anja ten; Verstegen, Niels J M; Zwinderman, Koos; Ham, S. Marieke van; Kuijpers, Taco W.; Rispens, Theo; Eftimov, Filip

doi:10.1136/ard-2022-223464

Cited by 5 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In solvent precipitation, the addition of phosphate and calcium ions causes the formation of calcium phosphate nanoparticles in solution. The co-precipitation of the drug and calcium phosphate is typically how the co-precipitation method produces the drug's carrier [137][138][139][140]. In addition, mannose-modified lipid calcium phosphate nanoparticles have attracted much attention in recent years [141].…”

Section: Preparation Methods and Structural Advantagesmentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as a potential therapeutic strategy. The potential role of the mannose-modified lipid calcium phosphate nanoparticle vaccine in enhancing the anti-tumor immune response was investigated. The aim of this study was to investigate the effect of mannose modification on the immune response of nanoparticles in regulating the tumor microenvironment through systematic review and analysis and to explore its potential clinical application in tumor therapy. Currently, despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and overexpression of immunosuppressive factors limit its clinical application. Therefore, this study will explore how to intervene in the immunosuppressive mechanism in the tumor microenvironment through mannose-modified lipid calcium phosphate nanoparticle vaccines so as to improve the immunotherapy effect of tumor patients and provide new ideas and strategies for the field of tumor therapy.

show abstract

Section: Preparation Methods and Structural Advantagesmentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

Stalman,

Wieske,

Keijser

et al. 2024

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID

Kummer,

Fernández Blanco,

Kreher

et al. 2024

RMD Open

View full text Add to dashboard Cite

ObjectivesMethotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerability of these patients to emerging infections and following vaccination.MethodsIn the current study, we investigated the impact of MTX treatment in patients with immune-mediated inflammatory disease on B and CD4 T cell SARS-CoV-2 vaccination responses. Eighteen patients with RA and two patients with psoriatic arthritis on MTX monotherapy were included, as well as 10 patients with RA without immunosuppressive treatment, and 29 healthy controls. CD4 T and B cell responses were analysed 7 days and 3–6 months after two SARS-CoV-2 messenger RNA vaccinations. High-dimensional flow cytometry analysis was used to analyse fresh whole blood, an activation-induced marker assay to measure antigen-specific CD4 T cells, and spike probes to study antigen-specific B cells.ResultsSeven days following two SARS-CoV-2 vaccinations, total B and T cell counts were similar between MTX-treated patients and controls. In addition, spike-specific B cell frequencies were unaffected. Remarkably, the frequency of antigen-specific CD4 T cells was reduced in patients using MTX and correlated strongly with anti-RBD IgG antibodies. These results suggest that decreased CD4 T cell activity may result in slower vaccination antibody responses in MTX-treated patients.ConclusionTaken together, MTX treatment reduces vaccine-induced CD4 T cell activation, which correlates with lower antibody responses.Trial registration numberNL8900.

show abstract

Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases

Cited by 5 publications

References 7 publications

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID

Contact Info

Product

Resources

About